{"id":"haic-of-oxa","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Catheter-related complications"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hepatic arterial infusion chemotherapy (HAIC) is a regional delivery technique that administers oxaliplatin (a platinum-based chemotherapy agent) directly into the hepatic artery supplying liver tumors. This approach concentrates the drug at the tumor site while reducing systemic toxicity. Oxaliplatin works by forming DNA adducts that inhibit DNA replication and transcription, leading to cancer cell death.","oneSentence":"HAIC of OXA delivers oxaliplatin directly into the hepatic artery to achieve high local chemotherapy concentration in liver tumors while minimizing systemic exposure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:51.273Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (HCC)"},{"name":"Liver metastases from colorectal cancer"}]},"trialDetails":[{"nctId":"NCT05877001","phase":"PHASE2","title":"The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2023-05-30","conditions":"Colorectal Liver Metastases","enrollment":20},{"nctId":"NCT05519410","phase":"PHASE2","title":"Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-08-23","conditions":"Resectable Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT04479527","phase":"PHASE2","title":"Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2021-04","conditions":"Hepatocellular Carcinoma","enrollment":34},{"nctId":"NCT04687163","phase":"PHASE3","title":"Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-12-30","conditions":"Hepatocellular Carcinoma","enrollment":400},{"nctId":"NCT03812770","phase":"PHASE2","title":"Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-08-04","conditions":"Hepatocellular Carcinoma","enrollment":150},{"nctId":"NCT03468231","phase":"PHASE3","title":"HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-03-09","conditions":"Hepatocellular Carcinoma","enrollment":300},{"nctId":"NCT02767375","phase":"PHASE2, PHASE3","title":"Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2015-02","conditions":"Hepatocellular Carcinoma","enrollment":192},{"nctId":"NCT01997957","phase":"PHASE4","title":"A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC","status":"UNKNOWN","sponsor":"Zhu Xu","startDate":"2013-10","conditions":"Hepatocellular Carcinoma","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oxaliplatin"],"phase":"phase_3","status":"active","brandName":"HAIC of OXA","genericName":"HAIC of OXA","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HAIC of OXA delivers oxaliplatin directly into the hepatic artery to achieve high local chemotherapy concentration in liver tumors while minimizing systemic exposure. Used for Hepatocellular carcinoma (HCC), Liver metastases from colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}